Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary)
  • Indications Endometriosis; Pelvic pain
  • Focus Registrational; Therapeutic Use
  • Acronyms ELARIS EM-II; ELARIS-II; EM-II; Solstice
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 25 Oct 2019 Results evaluating the impact of elagolix on endometriosis related workplace and household productivity losses using pooled data from two trials (NCT01931670 and NCT01620528) published in The Patient - Patient-Centered Outcomes Research
    • 18 Jun 2019 Results of a post-hoc analysis of Elaris I and II trials assessing the impact assessing of elagolix on work loss due to endometriosis-associated pain, published in the Fertility and Sterility
    • 05 Jun 2019 This trial has been completed in Italy, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top